Yokoya F, Nakayama T, Sakamoto K, Ohhira K, Ohshika Y, Mori Y, Toyoshi K, Nagai H, Koda A
Jpn J Pharmacol. 1984 Jan;34(1):23-31. doi: 10.1254/jjp.34.23.
The effects of (+/-)-2-[p-(2-thenoyl)phenyl] propionic acid (suprofen), a new anti-inflammatory agent, on experimental allergic reaction and antibody formation were examined. The action was compared with those of ketoprofen, ibuprofen, indomethacin, tranilast, chlorpheniramine, prednisolone and/or cyclophosphamide. Suprofen inhibited homologous PCA in rats, immunological histamine release from rat peritoneal mast cells and guinea pig lung tissues, Forssman cutaneous vasculitis (FCV) and the Arthus reaction in guinea pigs. The potency for inhibition of the PCA reaction was similar to that of ketoprofen and more potent than ibuprofen and trailast. As for the release of anaphylactic mediators, suprofen was less potent than tranilast in terms of histamine release, but not the release of the slow reacting substance of anaphylaxis (SRS-A). Suprofen inhibited FCA more potently than other nonsteroidal anti-inflammatory drugs (NSAID). The inhibition of the Arthus reaction by suprofen was similar to those of other NSAID and prednisolone. Suprofen hardly affected delayed hypersensitivity in guinea pigs and antibody (IgM or IgE) formation in mice or rats.
研究了新型抗炎药(±)-2-[对-(2-噻吩甲酰基)苯基]丙酸(舒洛芬)对实验性过敏反应和抗体形成的影响。将其作用与酮洛芬、布洛芬、吲哚美辛、曲尼司特、氯苯那敏、泼尼松龙和/或环磷酰胺的作用进行了比较。舒洛芬可抑制大鼠的同种被动皮肤过敏反应(PCA)、大鼠腹膜肥大细胞和豚鼠肺组织的免疫性组胺释放、福斯曼皮肤血管炎(FCV)以及豚鼠的阿瑟斯反应。其抑制PCA反应的效力与酮洛芬相似,且比布洛芬和曲尼司特更强。至于过敏介质的释放,就组胺释放而言,舒洛芬的效力低于曲尼司特,但对过敏反应慢反应物质(SRS-A)的释放并非如此。舒洛芬抑制福斯曼皮肤血管炎的效力比其他非甾体抗炎药(NSAID)更强。舒洛芬对阿瑟斯反应的抑制作用与其他NSAID和泼尼松龙相似。舒洛芬对豚鼠迟发型超敏反应以及小鼠或大鼠抗体(IgM或IgE)形成几乎没有影响。